Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy
Designation based on 12-month primary endpoint data from GATHER pivotal trials
Avacincaptad pegol (ACP) is the only investigational product for treatment of GA to achieve two positive phase 3 pivotal trials with statistical significance
In...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news